Correlation Engine 2.0
Clear Search sequence regions

To evaluate the effect of clofibrate for unconjugated hyperbilirubinemia in neonates. A systematic review with meta-analysis of randomized controlled trials or quasi-randomized controlled trials was conducted to evaluate the clofibrate treatment in neonates with unconjugated hyperbilirubinemia. We followed the guidelines from the Cochrane review group and the PRISMA statement. Of 148 studies identified, a total of 13 studies on 867 infants were included. A single oral administration of clofibrate was associated with decreased need of phototherapy (RR:.38, 95% CI: 0.21 to 0.68), shortened duration of phototherapy (mean duration: 23.88 h, 95% CI: 33.03 to -14.72 h) and reduced peak total serum bilirubin (mean duration: -1.62 mg/dL, 95% CI: 2.13 to -1.11 mg/dL). These effects were especially obvious in term infants and infants without hemolytic diseases. Data regarding mortality or kernicterus were not available from included studies. Clofibrate may have short-term benefits for the infants with hyperbilirubinaemia, especially for population of term infants and infants without hemolytic diseases. Large RCTs with long-term followup are required to verify the safety of clofibrate and assess its long-term effects.


Tao Xiong, Dapeng Chen, Zhoujin Duan, Yi Qu, Dezhi Mu. Clofibrate for unconjugated hyperbilirubinemia in neonates: a systematic review. Indian pediatrics. 2012 Jan;49(1):35-41

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 22318100

View Full Text